Trials / Withdrawn
WithdrawnNCT04939311
Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Priscilla Hsue, MD · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 | One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks. |
| DRUG | Placebo | One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks. |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2026-07-01
- Completion
- 2027-07-01
- First posted
- 2021-06-25
- Last updated
- 2022-09-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04939311. Inclusion in this directory is not an endorsement.